Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib phosphate cream plus mucopolysaccharide polysulfate vs emollient in mild-to-moderate atopic dermatitis
ChiCTR2600130222Phase 4Not yet recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ruxolitinib in atopic dermatitis (AD) (2 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: Proportion of participants achieving IGA treatment success (IGA-TS) at Week 8. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600130222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130222.